The Online Investor
OLI Premium
Retiree Portfolio
Stock Option Ideas
Preferred Stock Newsletter

Slideshow Secondary Stock Offerings

By The Online Investor Staff, updated Fri., Apr. 29, 6:05 AM

Slide #14. Cellectar Biosciences, Inc. Secondary Offering

Company: Cellectar Biosciences, Inc. (NASDAQ:CLRB)
Date announced: 4/15/2016
Shares Offered: 3,286,384
Date of Pricing: 4/15/2016
Price Per Share: $2.13
Secondary Offering Details: Cellectar Biosciences, Inc. (NASDAQ:CLRB) ("Cellectar" or the "company") today announced the pricing of an underwritten public offering of common stock, or pre-funded warrants in lieu thereof, at a price of $2.13 per share and associated traditional warrants, for gross proceeds of approximately $7.0 million, prior to deducting underwriting discounts, commissions and offering expenses payable by the company.

Cellectar Biosciences is a biopharmaceutical company developing compounds for the treatment, diagnosis and imaging of cancer. Co.'s cancer-targeting technology permits selective delivery of a range of agents to cancer cells, including cancer stem cells. By attaching different agents to its phospholipid ether molecules as a cancer-targeting delivery platform, Co. develops product candidates with the potential to treat, diagnose and image a range of cancers. Co. is developing three product candidates: I-124-CLR1404, a cancer-targeting positron emission tomography imaging agent; I-131-CLR1404, a cancer-targeting molecular radiotherapeutic; and CLR1502, a non-radioactive optical imaging agent.
Open the CLRB Page at The Online Investor »

Company Name:  Cellectar Biosciences Inc
Sector:  Biotechnology

Open the CLRB Page at The Online Investor (in a new window) »

April 29, 2016    6:05 AM Eastern
Quotes delayed 20 minutes

Secondary Stock Offerings | | Copyright © 1998 - 2016, All Rights Reserved

Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes, powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.